Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group by T. De Pas et al.
Short Communication
Peptide receptor radiotherapy: a new option for the management
of aggressive fibromatosis on behalf of the Italian Sarcoma Group
T De Pas*,1, L Bodei2, G Pelosi3, F de Braud1, G Villa4, R Capanna5 and G Paganelli2
1Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435-I-20141, Milan, Italy; 2Division of Nuclear Medicine, European Institute
of Oncology, Via Ripamonti 435-I-20141, Milan, Italy; 3Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435-I-20141,
Milan, Italy; 4Division of Radiology, European Institute of Oncology, Via Ripamonti 435-I-20141, Milan, Italy; 52nd Division of Orthopedics and
Traumatology, CTO, Florence, Italy
The management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and
resistant to external-beam radiation therapy (EBRT). We report on two patients with fast-growing recurrences of AF resistant to
EBRT who obtained protracted clinical benefits with 90Y-DOTATOC. 90Y-DOTATOC should be further investigated in this setting.
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Peptide receptor radiotherapy, which uses radiolabelled peptides
that recognise tumour cell surface receptors, is a relatively new
technique for delivering large quantities of radioactivity to
tumours. The somatostatin analogue [DOTA0, Tyr3]octreotide
(DOTATOC) has been shown to be useful for this purpose, as it is
easily and stably labelled with yttrium-90. It has high affinity for
the somatostatin receptor subtype 2 (sst2) and a favourable bio-
distribution and safety profile in patients (Kwekkeboom et al,
2000). Tumour uptake of 90Y-DOTATOC can be revealed before
treatment by scintigraphy with 111In-labelled octreotide (OctreoS-
can) (Krenning et al, 1993). When 90Y-DOTATOC is given to
patients with cancers that express somatostatin receptors and show
adequate OctreoScan uptake, a good tumour –response rate is
observed (Cremonesi et al, 1999; Waldherr et al, 2001; Chinol et al,
2002).
Aggressive fibromatosis (AF) is a rare fibrous neoplasm with
biological behaviour intermediate between that of benign fibrous
lesions and malignant fibrosarcomas. The tumour is poorly
circumscribed and grows along tissue planes with an infiltrating-
like pattern towards mesenchymal tissue. The clinical equivalent to
this pathological behaviour is a high tendency to local recurrence.
Its management is problematic: adequate surgery is the first-choice
treatment; however, the lesion tends to recur locally even if
surgically removed with pathologically documented free-margin
resection. As systemic treatment options, chemotherapy, hormone
therapy and NSAIDs have been used with mixed success.
The response of AF to external-beam radiation (EBRT) is
documented, with a dose– response relation for tumour doses of
less than 50 Gy (Greenberg et al, 1981; Nuyttens et al, 2000).
However, there are AF cases that cannot be managed with EBRT
because of normal-tissue constraints, as there are cases that appear
to be resistant or refractory to EBRT.
According to these data, and to a report of partial AF regression
after prolonged treatment with the somatostatin-analogue lanreo-
tide (Mannant et al, 1995), we decided to investigate the usefulness
of 90Y-DOTATOC as a treatment for recurrent AF.
MATERIALS AND METHODS
Aggressive fibromatosis specimens from 10 patients were retro-
spectively examined for immunopositivity to a rabbit polyclonal
antibody anti-sst2A (cod SS-800, Biotrend Chemikalien, Germany).
Two specimens showed immunoreactivity to sst2. Next, we used
OctreoScan in six other patients with AF to test the expression of
sst2 receptors on the neoplasm.
Two patients had AF lesions that showed adequate OctreoScan
uptake (i.e., at least equal to one of the liver) and were hence
eligible for treatment with 90Y-DOTATOC. We explained to these
two patients the potential risks and benefits of this experimental
treatment, which had been approved by our Institute’s ethical
review board. They gave their written consent. An ongoing
phase I–II study using 90Y-DOTATOC in patients with solid
tumours (Paganelli et al, 2001; Chinol et al, 2002; Bodei et al, 2003)
was followed for these patients.
According to this protocol, patients had histologically confirmed
cancers expressing sst2 receptors, as documented by OctreoScan,
and documented residual disease or recurrence after conventional
treatment. DOTATOC was synthesised at the Division of
Radiological Chemistry, University Hospital, Basel using a
published procedure (Heppeler et al, 1999). Yttrium-90 chloride
was purchased from AEA Technology (Harwell, UK). DOTATOC
molecule was radiolabelled according to a published procedure
(Chinol et al, 2002). 90Y-DOTATOC was injected intravenously
over 20 min in 100 ml of physiological saline. Patients received
renal protection by infusing 10 g lysine hydrochloride in 500 ml of
saline over an hour before therapy and 15 g of lysine hydrochloride
in 750 ml saline over 2 h after therapy. The patients were hos-
pitalised for 2– 3 days after treatment in rooms set aside for
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radionuclide therapy, and were discharged only after the level of
specific activity in the urine had fallen below 0.037 MBq ml1, as
stipulated in the regulations governing use of radionuclides at our
centre.
Toxicity was evaluated according to WHO criteria (Miller et al,
1981). After discharge from hospital the patients underwent the
following tests: renal function, hepatic function, LDH and
uricaemia every 30 days, complete blood count every 15 days for
the first 2 months and monthly subsequently.
RESULTS
Case 1
The first patient, a 30-year-old woman, had a local relapse of right-
thigh AF. Nine months after the primary tumour had been
radically removed, she underwent further surgery for a local
relapse; however, during subsequent adjuvant external-beam
radiotherapy the disease again recurred and grew rapidly. The
patient received i.v., 90Y-DOTATOC in five cycles over 14 months,
cumulative activity 10.6 GBq. There was a partial response on MRI
according to WHO criteria after the first cycle (2.22 GBq) which
has lasted for more than 37 months (Figures 1 and 2).
Case 2
The second patient was a 22-year-old man with AF of the right
thigh. After radical surgery and adjuvant radiotherapy (44 Gy
external-beam and 27 Gy brachytherapy), there were four relapses
in the following 4 years. The relapses were removed surgically and
postoperative external-beam reirradiation (35 Gy) was given after
the third operation.
For the fifth relapse, characterised by rapid growth, conservative
surgery and radiotherapy were no longer possible, and as an
alternative to amputation we administered a cumulative activity of
8.18 GBq of 90Y-DOTATOC in three cycles over 4 months. There
was a disease stabilisation on MRI according to WHO criteria after
the first cycle (3.26 GBq) and disease has remained stable for more
than 19 months.
90Y-DOTATOC was very well tolerated in these patients, and
neither acute nor late toxicity was observed.
DISCUSSION
Patients with recurrent AF after full exploitation of the standard
therapy modalities such as surgery and EBRT are lacking other
local therapeutic options. In this communication, we report on two
patients with fast-growing recurrence of AF that appeared to be
resistant to appropriate EBRT.
Both patients obtained a protracted clinical benefit with a
peptide receptor radiotherapy with 90Y-DOTATOC in the absence
of acute and late toxicity. The excellent tolerability of this
experimental treatment is consistent with the results of our phase
I– II study (Paganelli et al, 2001; Chinol et al, 2002; Bodei et al, in
press). In this study, toxicity due to 90Y-DOTATOC, which was
mainly haematological, occurred in a minority of patients
receiving high activities per cycle (grade III toxicity in three out
of seven F 43% F of the patients receiving 5.18 GBq, defined
as MTD/cycle) and tended to reverse within 4 weeks. Neither
permanent renal toxicity nor other forms of toxicity were
observed.
To our knowledge, this is the first report showing that
90Y-DOTATOC can provide clinical benefits in patients with AF,
and the benefit obtained supports further investigation in this
setting. An OctreoScan should first be performed on a candidate
patient with AF and if adequate tumour uptake is observed,
90Y-DOTATOC could be considered as a further treatment option
to increase the chance of obtaining disease control.
Figure 1 The patient had a local relapse of right-thigh aggressive
fibromatosis: a scintigraphy with 111In-labelled octreotide (OctreoScan)
revealed tumour uptake of the radiopeptide (arrow).
Figure 2 (A) Magnetic resonance (SE FS T1W post Gd-DTPA Image) showed a local relapse of right-thigh aggressive fibromatosis (arrow). (B) A partial
response of disease (WHO criteria) was obtained by treating with 90Y-DOTATOC (SE T1W post Gd-DTPA magnetic resonance image).
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